Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Urogen Pharma Ltd (URGN)

Urogen Pharma Ltd (URGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
UroGen Pharma Reports Second Quarter 2019 Financial Results and Recent Corporate Developments

--Final Topline UGN-101 Phase 3 Data from OLYMPUS Trial to be Announced in Q3 2019

URGN : 32.01 (+2.50%)
UroGen Pharma to Report Second Quarter 2019 Financial Results on Friday, August 9, 2019

UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report second quarter 2019 financial results on Friday, August 9, 2019, prior to the open of the market. The announcement will be followed...

URGN : 32.01 (+2.50%)
UroGen Pharma Sees Hammer Chart Pattern: Time to Buy?

UroGen Pharma Ltd. (URGN) has been struggling lately, but the selling pressure may be coming to an end soon.

URGN : 32.01 (+2.50%)
UroGen Pharma Reports First Quarter 2019 Financial Results and Recent Corporate Developments

--Completion of UGN-101 Rolling NDA Submission to the FDA On Track for 2H 2019

URGN : 32.01 (+2.50%)
UroGen Delivers Updated Complete Response (CR) and Durability Data from the UGN-101 Phase 3 OLYMPUS Trial

--Six-month Durability Strong with 89 Percent of Evaluable Patients Remaining in CR

URGN : 32.01 (+2.50%)
UroGen Pharma to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019

UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report first quarter 2019 financial results on Thursday, May 9, 2019, prior to the open of the market. The announcement will...

URGN : 32.01 (+2.50%)
UroGen Pharma Announces Early Stage Feasibility Agreement with Janssen

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of uro-oncology, today announced that it has entered...

URGN : 32.01 (+2.50%)
New Research: Key Drivers of Growth for Ironwood Pharmaceuticals, State Street, CMS Energy, Virtus Investment Partners, Capstone Turbine, and UROGEN PHARMA -- Factors of Influence, Major Initiatives and Sustained Production

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD),...

CPST : 0.65 (+2.08%)
STT : 50.20 (+2.85%)
VRTS : 99.20 (+3.38%)
URGN : 32.01 (+2.50%)
IRWD : 8.77 (-2.23%)
CMS : 61.20 (-0.11%)
UroGen Pharma Announces Presentation of Analysis from Phase 3 OLYMPUS Trial of UGN-101 for Patients with Low-Grade Upper Tract Urothelial Cancer

UroGen Pharma Ltd.(Nasdaq: URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced a new presentation from the pivotal...

URGN : 32.01 (+2.50%)
UroGen Pharma to Present at March 2019 Investor Conferences

UroGen Pharma Ltd. (Nasdaq:URGN), today announced that management will present at two investor conferences in March:

URGN : 32.01 (+2.50%)
UroGen Pharma to Report Fourth Quarter and Full Year 2018 Financial Results

--Acceleration of Pre-Commercial Activities and Infrastructure Buildout Underway to Support the Potential U.S. Approval and Launch of UGN-101 in 1H 2020

URGN : 32.01 (+2.50%)
UroGen Pharma to Report Fourth Quarter and Full Year 2018 Financial Results on Thursday, February 28, 2019

UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report fourth quarter and full year 2018 financial results on Thursday, February 28, 2019, prior to the open of the market. The...

URGN : 32.01 (+2.50%)
Factors of Influence in 2019, Key Indicators and Opportunity within Toyota Motor, UROGEN PHARMA, Macerich, Cosan, Middlesex Water, and Howard Hughes -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Toyota Motor Corporation...

CZZ : 13.58 (+3.90%)
HHC : 129.52 (+1.18%)
URGN : 32.01 (+2.50%)
TM : 128.79 (+1.12%)
MSEX : 60.81 (+0.66%)
MAC : 29.30 (-1.94%)
UroGen Pharma Announces Closing of Public Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced...

URGN : 32.01 (+2.50%)
JPM : 107.72 (+2.40%)
UroGen Pharma Announces Proposed Public Offering of Ordinary Shares

UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced...

URGN : 32.01 (+2.50%)
JPM : 107.72 (+2.40%)
UroGen Pharma Announces Positive Results of UGN-101 from Pivotal Phase 3 OLYMPUS Trial for the Non-Surgical Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer (LG UTUC)

--All Evaluated Patients in CR Remain Disease Free at Six Months

URGN : 32.01 (+2.50%)

Van Meerten Stock Picks

AMD - Volume Leader
The Volume Leader today is the semiconductor company Advanced Micro Devices (AMD).
AMD +1.51
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar